Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Letters: Observations

Elevated Serum Concentration of Adipose-Derived Factor, Adiponectin, in Patients With Type 1 Diabetes

  1. Akihisa Imagawa, MD, PHD,
  2. Tohru Funahashi, MD, PHD,
  3. Tadashi Nakamura, MD, PHD,
  4. Makoto Moriwaki, MD, PHD,
  5. Sachiyo Tanaka,
  6. Hitoshi Nishizawa, MD, PHD,
  7. Kouichi Sayama, MD,
  8. Sae Uno, MD,
  9. Hiromi Iwahashi, MD, PHD,
  10. Kazuya Yamagata, MD, PHD,
  11. Jun-ichiro Miyagawa, MD, PHD and
  12. Yuji Matsuzawa, MD, PHD
  1. From the Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University
    Diabetes Care 2002 Sep; 25(9): 1665-1666. https://doi.org/10.2337/diacare.25.9.1665
    PreviousNext
    • Article
    • Info & Metrics
    • PDF
    Loading

    Adiponectin, also referred to as Acrp30, AdipoQ, and GBP28, is a plasma protein exclusively produced by adipose tissue and a possible insulin-sensitizing agent (1–6). Serum adiponectin levels are negatively correlated to BMI in healthy individuals and decreased in type 2 diabetic patients (1–6). However, serum adiponectin levels in type 1 diabetes have not been elucidated.

    We examined the serum adiponectin concentrations in 46 type 1 diabetic patients (21 males and 25 females) and compared them with those of BMI-matched healthy control subjects (17 males and 19 females). Mean age was 33 ± 3 and 33 ± 4 years, BMI was 19.8 ± 0.5 and 19.9 ± 0.6 kg/m2, HbA1c level was 9.7± 0.7 and 10.4 ± 0.6%, duration of diabetes was 3.2 ± 0.9 and 3.4 ± 1.3 years, and urinary C-peptide excretion was 18.4 ± 4.3 and 18.0 ± 2.4 μg/day in male and female patients, respectively. High prevalence of GAD antibody or islet cell antibodies (91.3%) indicated autoimmune-associated β-cell destruction in those patients. Two patients suffered from simple diabetic retinopathy, and two other patients had microalbuminuria, but no patient suffered from macroalbuminuria, continuous proteinuria, or elevated serum creatinin. All patients revealed normal electrocardiogram at rest. In the control group, mean age was 34 ± 1 and 33 ± 2 years and BMI was 20.8 ± 0.4 and 20.2 ± 0.5 in males and females, respectively. There were no significant differences in age and BMI between type 1 diabetic patients and control subjects, in either males or females. Informed consent was obtained from all patients and healthy control subjects. Serum adiponectin levels were determined by enzyme-linked immunosorbent assay (2). Intra- and interassay variation in our laboratory was 3.3 and 7.4%, respectively. Unexpectedly, serum adiponectin levels were markedly higher in type 1 diabetic patients (13.6 ± 1.8 μg/ml in males, and 16.1 ± 1.6 μg/ml in females) than in healthy control subjects (6.9 ± 0.7 μg/ml in males and 10.0 ± 0.8 μg/ml in females, respectively; P < 0.01).

    Serum adiponectin levels also were determined before and during the insulin replacement therapy in seven patients. Exogenous insulin (0.49 ± 0.10 units · kg−1 · day−1) had been injected for 1.9 ± 0.7 years after the onset of overt diabetes. HbA1c levels before and during insulin therapy were 10.7 ± 1.3 and 8.2 ± 1.1%, and BMI was 18.3 ± 0.5 and 20.0 ± 0.6 kg/m2, respectively. There was no significant difference in serum adiponectin levels before (11.5 ± 1.3 μg/ml) and during insulin therapy (14.3 ± 3.7 μg/ml) .

    Our results have demonstrated that serum adiponectin levels, which have been reported to decrease in type 2 diabetes (3,4), surprisingly increased in type 1 diabetes. Plasma glucose or insulin concentration is a possible regulator of circulating adiponectin level. Among them, hyperglycemia is a common feature of type 1 and type 2 diabetes. Therefore, hyperglycemia itself is not a critical determinant for circulating adiponectin level in vivo.

    Chronic exposure of insulin decreased the gene expression of adiponectin in the cultured 3T3-L1 adipocytes (7), suggesting that absolute insulin deficiency may contribute to elevated level of serum adiponectin in type 1 diabetes. However, our longitudinal study showed insulin therapy did not change serum adiponectin levels in type 1 diabetic patients. Berg et al. (6) demonstrated that circulating levels of adiponectin did not change before or after the onset of overt diabetes in NOD mice, although serum insulin levels dramatically decreased after the onset of diabetes. Therefore, factors other than plasma glucose and insulin levels must play a significant role in controlling the serum adiponectin concentration in type 1 diabetes.

    Recently, it has been reported that leptin, another adipocyte-derived protein, modulates T-cell immune response (8) and accelerates the development of autoimmune diabetes in NOD mice (9). We have previously reported that adiponectin modulates the expression of endothelial adhesion molecules in vitro (10), which were dysregulated in the pancreas of type 1 diabetic patients (11). Our present results have indicated that serum adiponectin levels increased in type 1 diabetes, suggesting that adiponectin, an adipocyte-derived protein, might influence immune responses as leptin does in autoimmune diabetes.

    Acknowledgments

    This study was supported in part by a grant from the Japanese Ministry of Education, Culture, Sports, Science and Technology (14013038), a grant from Kanae Foundation for life and socio-medical science, and a grant from Senri Life Science Foundation.

    Footnotes

    • Address correspondence to Akihisa Imagawa, MD, FACP, Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, 2-2-B5 Yamadaoka, Suita 565-0871, Japan. E-mail: imagawa{at}imed2.med.osaka-u.ac.jp.

    • DIABETES CARE

    References

    1. ↵
      Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1). Biochem Biophys Res Commun 221:286–289, 1996
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83, 1999
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599, 2000
      OpenUrlAbstract/FREE Full Text
    4. ↵
      Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935, 2001
      OpenUrlCrossRefPubMedWeb of Science
    5. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946, 2001
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953, 2001
      OpenUrlCrossRefPubMedWeb of Science
    7. ↵
      Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R: Hormonal regulation of adiponectin gene expression in 3T3–L1 adipocytes. Biochem Biophys Res Commun 290:1084–1089, 2002
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI: Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394:897–901, 1998
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      Matarese G, Sanna V, Lechler RI, Sarvetnick N, Fontana S, Zappacosta S, La Cava A: Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes 51:1356–1361, 2002
      OpenUrlAbstract/FREE Full Text
    10. ↵
      Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476, 1999
      OpenUrlAbstract/FREE Full Text
    11. ↵
      Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K, Waguri M, Imagawa A, Tamura S, Inada M, Kawata S, Tarui S, Kono N, Matsuzawa Y: Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 92:2313–2322, 1993
    PreviousNext
    Back to top
    Diabetes Care: 25 (9)

    In this Issue

    September 2002, 25(9)
    • Table of Contents
    • About the Cover
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes Care.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Elevated Serum Concentration of Adipose-Derived Factor, Adiponectin, in Patients With Type 1 Diabetes
    (Your Name) has forwarded a page to you from Diabetes Care
    (Your Name) thought you would like to see this page from the Diabetes Care web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Elevated Serum Concentration of Adipose-Derived Factor, Adiponectin, in Patients With Type 1 Diabetes
    Akihisa Imagawa, Tohru Funahashi, Tadashi Nakamura, Makoto Moriwaki, Sachiyo Tanaka, Hitoshi Nishizawa, Kouichi Sayama, Sae Uno, Hiromi Iwahashi, Kazuya Yamagata, Jun-ichiro Miyagawa, Yuji Matsuzawa
    Diabetes Care Sep 2002, 25 (9) 1665-1666; DOI: 10.2337/diacare.25.9.1665

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Elevated Serum Concentration of Adipose-Derived Factor, Adiponectin, in Patients With Type 1 Diabetes
    Akihisa Imagawa, Tohru Funahashi, Tadashi Nakamura, Makoto Moriwaki, Sachiyo Tanaka, Hitoshi Nishizawa, Kouichi Sayama, Sae Uno, Hiromi Iwahashi, Kazuya Yamagata, Jun-ichiro Miyagawa, Yuji Matsuzawa
    Diabetes Care Sep 2002, 25 (9) 1665-1666; DOI: 10.2337/diacare.25.9.1665
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Acknowledgments
      • Footnotes
      • References
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Weight Gain and Gestational Diabetes Mellitus Is a Sensitive Issue
    • Beneficial Effects of a 4-Week Exercise Program on Plasma Concentrations of Adhesion Molecules
    • Malignant Melanoma Misdiagnosed as a Diabetic Foot Ulcer
    Show more Letters: Observations

    Similar Articles

    Navigate

    • Current Issue
    • Standards of Care Guidelines
    • Online Ahead of Print
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.